IDCRC Newsletter: October 2025

IDCRC Publishes Supplement in Clinical Infectious Diseases (CID)

It highlights the value and impact of the collaborative partnerships among the National Institute of Allergy and Infectious Diseases (NIAID), the IDCRC Leadership Group, and the IDCRC VTEUs, as well as the global network of partner sites, all working together to improve the treatment and prevention of infectious diseases and to respond effectively to public health emergencies.

IDCRC shines at IDWeek 2025

IDWeek 2025 was held earlier this month in Atlanta, GA, from October 19-22. More than 11,000 infectious disease health professionals from various institutions and backgrounds worldwide gathered to collaborate, connect, and learn from each other’s expertise in patient care, research, and public health.

"The conference provided a perfect venue to connect with Peds and Adult ID colleagues and to hear updates on cutting-edge research advances in ID. At the same time, it was a sobering reminder of the many challenges that absent colleagues from the U.S. CDC and military continue to face in doing their work. While we celebrated achievements and successes, we acknowledged the obstacles that we must overcome together to achieve all that we can for public health." — Matthew B. Laurens, MD, MPH, University of Maryland

The IDCRC was well represented, with 42 presentations delivered by our members.

We are proud to highlight a few of these individuals below and many more in the full recap story on the IDCRC website.

• IDCRC mentoring cohort members Paulina Sudnik, MD, and Cristina Tomatis Souverbielle, MD, each delivered a poster presentation. 
• Robert Frenck, MD, Cincinnati Children’s Hospital Medical Center VTEU PI, Christina A. Rostad, MD, director of the Emory Children’s Center Vaccine Research Clinic, and Jennifer Whitaker, MD, MSc, Baylor VTEU investigator, served as panelists in an interactive session titled “Challenging Vaccine Issues: Beyond the Guidelines,” moderated by C. Mary Healy, MD, COU co-director and Flor Munoz, MD, Baylor VTEU investigator. 

Congratulations again to our VTEU partners and IDCRC members on being selected for these opportunities! 

Spotlight: "LARC2" Study Protocol Co-Chair, Sean C. Murphy, MD

Dr. Murphy is an assistant director of clinical microbiology and associate professor of laboratory medicine at the University of Washington (UW) School of Medicine. Dr. Murphy’s work focuses on the immune response to complex infectious diseases and on diagnostic test development. The major focus of the laboratory is malaria infection of humans and animal models by Plasmodium parasites.

"Because of the collaboration across IDCRC, NIH, and the VTEUs, we are able to continue to advance malaria vaccines, critical to maintain support and focus in our collective fight against this hugely important parasite. Malaria is mostly thought of as a tropical disease, but it is important to remember that 100 years ago there were over one million cases annually in the U.S. (i.e., the conditions can exist for transmission here) and even this year and in the past few years there have been cases of malaria transmitted by local mosquitoes in the U.S. to Americans who had not traveled outside of the U.S."

Annual Meeting

Put it on your calendar: 2026 Annual Meeting

Training

IDCRC Mentee Profile: Andrew B. Flemimg, MD

"I’m very grateful to be included in the IDCRC mentorship program. I look forward to learning from all my inspiring colleagues, hearing about their research interests, and, hopefully, developing relationships for future collaborations."

MCDC Mentoring Lecture Series

The IDCRC Mentoring Lecture Series brings the IDCRC mentees together with leading experts to discuss topics related to the VTEUs, vaccinology, and clinical trials development and management. Check out our recent lecture below!

October Lecture: Time Management Techniques

News

IDSA | "RSV Immunization in Infants Is Safe and Provides High Antibody Levels Regardless of Mother’s Vaccination Status"

This study is ongoing as researchers will follow up with participants to access immune durability for one year in mothers, infants and in breast milk. While the vaccine is proven to be safe and well tolerated in infants, researchers say durability of immunity for mothers and infants has yet to be fully described. The study is being conducted by the Infectious Diseases Clinical Research Consortium through funding from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health (UM1AI48684).

NYU Langone Health launches Transplant ID Fellowship Program

Contemporary Pediatrics spotlights C. Buddy Creech, MD

NFID Infectious IDeas | Fact vs. Fiction: Top Vaccine Myths Debunked with Kathy Neuzil, MD, MPH

Job Postings

Newly Posted! Infectious Diseases Research Job Openings

• Northwestern Medicine - Infectious Diseases Clinician-Educator
• Rush University Medical Center - Microbial, Pathogens & Immunity Research Faculty

• The Ohio State University Wexner Medical Center - Post Doctoral Scholar - Microbial Infection & Immunity

• University of Birmingham at Alabama (UAB) - Postdoctoral Position in Biochemistry and Electron Microscopy of Membrane Proteins 

Visit the IDSA Career Center to browse other ID/HIV Medicine job postings.

Funding Opportunities

IDCRC Studies

Active Studies Recruiting Volunteers

• A Phase 4 Study of a 3-Day vs. 7-Day Regimen of Doxycycline for the Treatment of Chlamydial Infection (DMID 22-0019)

Fully Enrolled Studies in Follow-up

• A Randomized, Double-Blind, Placebo-Controlled Phase 1 Trial to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of Sanaria(R) PfSPZ-LARC2 Vaccine, a Late-Arresting, Replication-Competent, Genetically Attenuated Plasmodium Falciparum Vaccine by Controlled Human Malaria Infection in Malaria-Naïve Healthy Adults Conditions (DMID 23-0010)
• Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults (DMID 23-0006)

• A Phase 1 Trial to Evaluate the Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine, HydroVax-001B WNV in Healthy Adults (DMID 24-0008)

• Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine (DMID 22-0020A)

• A Phase 1, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Safety and Pharmacokinetics of a Single Ascending Dose of EV-D68-228 in Healthy Adult Volunteers (DMID 23-0005)

• A Prospective, Randomized, Open-label Phase 4 Study of the Immunology and Safety of Maternal RSV Vaccination (ABRYSVOTM), Infant Nirsevimab (BEYFORTUSTM) Immunization, or Both Products During the First Year of Life (PROMISE) (DMID 24-0003)

IDCRC Concept Quick Stats

Communication Resources

Please submit IDCRC news to idcrc@emory.edu for inclusion in the monthly newsletter and IDCRC.org.